Company Profile
Ironwood Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- IRWD
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.26 USD (+2.65%)
Close
Last updated: August 6, 2026
540M USD
Market cap
Why the stock is moving
Following the latest company update, “Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results”, IRWD closed up 2.65% at $4.26 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Business overview
Ironwood Pharmaceuticals is a gastrointestinal-focused company anchored by Linzess and a pipeline aimed at digestive health. Its story is centered on GI commercialization and pipeline extension.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Ironwood sits in specialty biopharma.
Business Model Characteristics
The business combines commercial GI revenue with pipeline optionality, so investors track prescription trends, partnership economics, and product durability.
Position Within the Biotechnology Landscape
Ironwood is a commercial specialty-pharma name whose valuation is tied to a limited number of digestive-health assets and their lifecycle.
Future catalysts
Ironwood's catalysts are Linzess execution, GI commercial stability, and any pipeline or partnership update that clarifies the next growth vector. The company still needs the core franchise to stay durable.
Recent news
- 01
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
Source: Ironwood Pharmaceuticals
- 02
Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
Source: Ironwood Pharmaceuticals
- 03
- 04
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Source: Ironwood Pharmaceuticals
- 05
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
Source: Ironwood Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Ironwood Pharmaceuticals (IRWD)?
Ironwood Pharmaceuticals (IRWD) most recently closed at 4.26 USD, a +2.65% move versus the previous session.
What is the market cap of Ironwood Pharmaceuticals (IRWD)?
Ironwood Pharmaceuticals currently has a market capitalization of 540M USD on BioPharmSignal.
What does Ironwood Pharmaceuticals do?
Ironwood Pharmaceuticals is a gastrointestinal-focused company anchored by Linzess and a pipeline aimed at digestive health. Its story is centered on GI commercialization and pipeline extension.
On which exchange is IRWD stock listed?
Ironwood Pharmaceuticals (IRWD) is associated with NASDAQ, United States, Biopharma.
What is Ironwood?
Ironwood's catalysts are Linzess execution, GI commercial stability, and any pipeline or partnership update that clarifies the next growth vector.
Which conditions is Ironwood Pharmaceuticals targeting with Ironwood?
Ironwood's catalysts are Linzess execution, GI commercial stability, and any pipeline or partnership update that clarifies the next growth vector.
How does Ironwood Pharmaceuticals describe recent progress with Ironwood?
Ironwood's catalysts are Linzess execution, GI commercial stability, and any pipeline or partnership update that clarifies the next growth vector.
What is Pharmaceuticals?
Ironwood Pharmaceuticals is a gastrointestinal-focused company anchored by Linzess and a pipeline aimed at digestive health.